Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer science. 2023. 114. 12. 4643-4653
Takahiro Haeno, Shinya Rai, Yoshiaki Miyake, Maiko Inoue, Ko Fujimoto, Aki Fujii, Yoshio Iwata, Shuji Minamoto, Takahide Taniguchi, Hiroaki Kakutani, et al. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2023. 63. 2. 99-107
Ryosuke Fujiwara, Yasuhiro Taniguchi, Shinya Rai, Yoshio Iwata, Aki Fujii, Ko Fujimoto, Takahiro Kumode, Kentaro Serizawa, Yasuyoshi Morita, J Luis Espinoza, et al. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Biochemical and biophysical research communications. 2022. 626. 156-166
Takahiro Kumode, Hirokazu Tanaka, Jorge Luis Esipinoza, Shinya Rai, Yasuhiro Taniguchi, Ryosuke Fujiwara, Keigo Sano, Kentaro Serizawa, Yoshio Iwata, Yasuyoshi Morita, et al. C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. International journal of hematology. 2022. 115. 3. 310-321
Kentaro Serizawa, Hirokazu Tanaka, Takeshi Ueda, Ayano Fukui, Hiroaki Kakutani, Takahide Taniguchi, Hiroaki Inoue, Takahiro Kumode, Yasuhiro Taniguchi, Shinya Rai, et al. CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. International Journal of Hematology. 2022. 115. 3. 336-349
SUMO化阻害薬とrituximabのマクロファージおよびNK細胞活性-The activity of macrophage and NK cell induced by the combined treatment with SUMOylation inhibitor and rituximab
科学評論社 2023
講演・口頭発表等 (50件):
フルダラビン+ブスルファンを用いた同種造血幹細胞移植における重症口腔粘膜炎発症のリスク因子の解析(Risk factor of oral mucositis after allogeneic hematopoietic stem cell transplantation using FLU/BU)
(日本血液学会学術集会 2021)